Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
The FDA has approved the use of the injectable drug KORSUVA in treating moderate to severe pruritus in adult patients undergoing hemodialysis for chronic kidney disease.
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
Shoreline Biosciences was propelled into the proverbial catbird’s seat this summer with two mega-deals, and now plans to double its employee base from 50 to 100 in the coming months.
Anti-aging organization SENS Research Foundation sacked Chief Science Officer Aubrey de Grey over concerns he has attempted to influence an investigation of sexual harassment claims filed against him.